Search Results

Containing any of the words

Only of the type

Information for Healthcare Professionals: OnabotulinumtoxinA (marketed as Botox/Botox Cosmetic), Awareness Article

SFDA CEO: Inspector or field monitor assists and guides business owners and establishments to correct violations News

Montelukast as add-on therapy to inhaled corticosteroids in the treatment of mild to moderate asthma Awareness Article

A Randomized, Double-Blind, Placebo Controlled Cross- Over Study toInvestigate the Efficacy and Safety of SC0023, a Magnesium Salt Oral SprayDevice, in Adults with Refractory or Unexplained Chronic Cough Clinical Trial

A Phase 3, single-arm, multicenter, multinational, open label,one-way crossover study to investigate the efficacy and safety of fitusiran prophylaxis in male participants aged ≥ 12 years with severe hemophilia A or B, with or without inhibitory antibodies to factor VIII or IX Drug Clinical Trial

A Retrospective Chart Review Combined with a Prospective Cross-sectional Survey and Interviews on Patients with Type 2 Diabetes Mellitus to Assess Effectiveness of Adding SodiumGlucose Co-transporter 2 Inhibitor to Gliclazide Modified Release Drug Clinical Trial

"Study to Evaluate the Safety, Tolerability and Immunogenicity of INO-4700 for Middle East Respiratory Syndrome Coronavirus (MERS-CoV) in Healthy" Drug Clinical Trial

A 2-Part, Open-Label, Phase 2, Multiple Dose Study to Evaluate the Pharmacodynamic Effects, Safety, and Tolerability of Patiromer in Children under 12 Years of Age with Hyperkalaemia (EMERALD2) Drug Clinical Trial

A Phase 3, randomized, double-blind, placebo-controlled, parallel-group, 3-arm, multinational, multicenter study to evaluate the efficacy and safety of amlitelimab by subcutaneous injection in participants aged 18 years and older with moderate-to-severe atopic dermatitis (AD) who are on background topical corticosteroids and have had an inadequate response to prior biologic therapy or oral Janus Kinase (JAK) inhibitor treatment Drug Clinical Trial

A Phase II/III, Extension Study of Orally Administered PHA-022121 for Acute Treatment of Angioedema Attacks in Patients with Hereditary Angioedema due to C1-Inhibitor Deficiency (Type I or Type II (RAPIDe-2) Drug Clinical Trial